The Omega-3 Index: The Biomarker Most Cardiologists Are Not Checking
Defining the Omega-3 Index
The Omega-3 Index was first proposed by William Harris and Clemens von Schacky in their landmark 2004 paper in Preventive Medicine. It measures EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) as a percentage of total fatty acids in red blood cell membranes — a stable, 3-month rolling average of omega-3 status that reflects actual tissue incorporation rather than transient dietary intake.
A low Omega-3 Index (below 4%) is classified as high-risk. An optimal index (above 8%) is associated with the lowest cardiovascular event rates. The global average in Western populations sits at approximately 4–5%, reflecting the widespread dietary deficiency of EPA and DHA.
Cardiovascular Outcomes: The Evidence
In the JELIS trial (Yokoyama et al., 2007, The Lancet), 18,645 Japanese patients with hypercholesterolemia were randomized to statin therapy alone or statin + EPA 1.8g/day. The EPA group demonstrated a 19% reduction in major coronary events — a result achieved without any reduction in LDL cholesterol, suggesting an LDL-independent cardioprotective mechanism.
The REDUCE-IT trial (Bhatt et al., 2019, NEJM) extended this with EPA (icosapentaenoic acid ethyl ester) at 4g/day in statin-treated patients with elevated triglycerides, demonstrating a remarkable 25% relative risk reduction in cardiovascular events including cardiovascular death.
Anti-Inflammatory Mechanisms
EPA and DHA are precursors to specialized pro-resolving mediators (SPMs) — including resolvins, protectins, and maresins — that actively terminate inflammatory cascades rather than simply suppressing them. This resolution biology, pioneered by Charles Serhan at Harvard Medical School, explains why omega-3s reduce chronic low-grade inflammation (elevated hs-CRP) through a fundamentally different mechanism than NSAIDs or corticosteroids.
Testing and Optimization
Axel protocols include Omega-3 Index testing as a standard biomarker in the initial terrain assessment. Patients with an index below 6% receive Lipo® Odek (combining liposomal omega-3 with D3 and K2), with re-testing at 12 weeks to confirm therapeutic response. The dose required to achieve an index above 8% varies significantly by individual metabolism and baseline status.